Metraipolis › archive › dc_fba6cdaa042b

Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42336860
DOI
10.1038/s41467-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-10-19T05:43:24.144Z
SHA-256 of the archived text
788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b
Stable URL of this page
https://metraipolis.com/documento/dc_fba6cdaa042b

How to cite

Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860 — Europe PMC (en), https://europepmc.org/article/MED/42336860 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fba6cdaa042b (Metraipolis archive dc_fba6cdaa042b, sha256 788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b)
BibTeX
@misc{dcfba6cdaa042b,
  title = {Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42336860},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fba6cdaa042b; sha256 788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42336860. Agents can read the archived copy with the MCP tool read_document.